Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company engaged in the R&D of tissue-engineered and cell therapy products. Bonus CEO Dr. Shai Meretzki, one of Israel's most prominent biotech entrepreneurs, founded Bonus to build live tissues outside the body. He started with bones, developing BonoFill, the world's first tissue-engineered viable bone graft for treating severe bone defects currently under-treated by transplanting bone from another part of the body with considerable limitations. The active ingredients in BonoFill are mesenchymal cells isolated from the patient's adipose tissue. Using BonoFill, bones were successfully regenerated in already dozens of patients that recovered from years of disabilities. During the coronavirus outbreak, Bonus started developing MesenCure based on mesenchymal cells to treat life-threatening pneumonia and cytokine storm in severe Covid-19 patients. With excellent clinical results and established manufacturing capacity, Bonus strives to continue saving and improving patients' lives and becoming a world leader in regenerative medicine.
